Cell and gene therapy technologies are ascendent, boosted by new developments in treatments for diseases like ovarian cancer and Parkinson’s disease, and by predictions of a meteoric rise in total market value in the next five years. Fabian Gerlinghaus, the co-founder and CEO of Cellares, a company that has developed a so-called “factory-in-a-box” for cell and gene therapy manufacturing, joins the podcast to share Cellares’ unique approach to developing successful cell therapies, the regulatory landscape and why investors should be watching this sector.

***

The Middle Market Growth Conversations podcast is produced by the Association for Corporate Growth. To learn more about the organization and how to become a member, visit www.acg.org.

Ver todos los episodios